Orilanolimab
Modify Date: 2024-04-08 17:48:42
Orilanolimab structure
|
Common Name | Orilanolimab | ||
|---|---|---|---|---|
| CAS Number | 2066544-85-0 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of OrilanolimabOrilanolimab (SYNT001) is a humanized, de-immunized and FcRn-blocking monoclonal antibody. Orilanolimab blocks the interaction between FcRn and the Fc portion of IgG molecules. Orilanolimab impedes IgG IC activation of the FcRn-mediated adaptive immune function. And Orilanolimab disrupts the associated pathways related to IgG homeostasis and innate and adaptive immunity[1][2]. |
| Name | Orilanolimab |
|---|
| Description | Orilanolimab (SYNT001) is a humanized, de-immunized and FcRn-blocking monoclonal antibody. Orilanolimab blocks the interaction between FcRn and the Fc portion of IgG molecules. Orilanolimab impedes IgG IC activation of the FcRn-mediated adaptive immune function. And Orilanolimab disrupts the associated pathways related to IgG homeostasis and innate and adaptive immunity[1][2]. |
|---|---|
| Related Catalog | |
| Target |
Interaction between FcRn and IgG[1] |
| In Vitro | Orilanolimab (10nM、50nM和100nM；48小时) 抑制 B2MTG/TGFCGRTTG/TGFcgrt-/- 小鼠的 CD11c＜sup＞+[1]。 |
| In Vivo | Orilanolimab (20mg/kg；静脉注射) 显著降低小鼠模型中HuLys11的血浆浓度[1]。 Orilanolimab (10-100 mg/kg；静脉注射；每5周一次) 导致IgG食蟹猴总循环水平的剂量依赖性和特异性降低[1]。 |
| References |
| No Any Chemical & Physical Properties |